GSK126是一种高活性,S-腺苷-蛋氨酸竞争性EZH2甲基转移酶抑制剂,Ki为0.5 nM。
别名:EZH2 inhibitor; GSK2816126A
GSK126是一种高活性,S-腺苷-蛋氨酸竞争性EZH2甲基转移酶抑制剂,Ki为0.5 nM。GSK126 decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice.
体外实验* | |
---|---|
细胞系 | EZH2 wildtype or mutant B-cell lymphoma cell lines |
方法 | Cell proliferation assay. The optimal cell seeding was determined empirically for all cell lines by examining the growth of a wide range of seeding densities in a 384-well format to identify conditions that permitted proliferation for 6 days. Cells were then plated at the optimal seeding density 24 h before treatment (in duplicate) with a 20-point twofold dilution series of GSK126 or 0.15% DMSO. Plates were incubated for 6 days at 37℃ in 5% CO2. Cells were then lysed with CellTiter-Glo (CTG) (Promega) and chemiluminescent signal was detected with a TECAN Safire2 microplate reader. In addition, an untreated plate of cells was harvested at the time of compound addition (T0) to quantify the starting number of cells. CTG values obtained after the 6 day treatment were expressed as a percent of the T0 value and plotted against compound concentration. Data were fit with a four-parameter equation to generate a concentration response curve and the concentration of GSK126 required to inhibit 50% of growth (growth IC50) was determined. |
浓度 | 0~100µM |
处理时间 | 6 days |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
体内实验* | |
---|---|
动物模型 | Pfeiffer or KARPAS-422 cells tumour xenograft in mice |
配制 | 20% captisol adjusted to pH 4–4.5 with 1 N acetic acid. |
剂量 | 0.2 ml per 20 g body weight |
给药处理 | intraperitoneally |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
分子量 | 526.67 |
分子式 | C31H38N6O2 |
CAS号 | 1346574-57-9 |
溶解性(25°C) | DMSO 10 mg/mL |
储存条件 |
粉末型式 -20°C 3年;4°C 2年 溶于溶剂 -80°C 6个月;-20°C 1个月 |
运输方式 | 冰袋运输,根据产品的不同,可能会有相应调整。 |
*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.8987 mL | 9.4936 mL | 18.9872 mL |
5 mM | 0.3797 mL | 1.8987 mL | 3.7974 mL |
10 mM | 0.1899 mL | 0.9494 mL | 1.8987 mL |
小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 | |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km 系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
其他相关的EZH2产品 |
---|
Tulmimetostat
Tulmimetostat是一种有口服活性的 EZH1/EZH2 蛋白双重抑制剂,具有抗肿瘤活性,可用于多种实体瘤研究。 |
PF-06821497
PF-06821497是一种选择性和口服活性的Zeste Homolog 2 (EZH2)抑制剂,具有强大的肿瘤生长抑制作用。 |
CPI-1205
CPI-1205是一种有效的,选择性的,口服生物可利用的EZH2(组蛋白赖氨酸甲基转移酶)抑制剂(生化IC50 = 0.002μM,细胞EC50 = 0.032μM)。 |
Valemetostat
Valemetostat (DS-3201、DS-3201b)是一种首创的(first-in-class)的靶向EZH1和EZH2的双重抑制剂。可用于成人T细胞白血病/淋巴瘤的研究。 |
MS1943
MS1943 是一种首创的(first-in-class),具有口服生物活性的 EZH2 选择性降解剂,其IC50 为 120 nM。MS1943 显著降低了许多三阴性乳腺癌和其他癌及非癌细胞系中的EZH2蛋白水平。MS1943 有效地阻止了多个三阴性乳腺癌和其他癌细胞系的增殖。 |
产品仅供科学研究或药证申报的用途使用,不为任何个人或者非科研性质的其他用途提供服务。
Copyright © 2010-2022 AbMole版权所有 沪ICP备16047849号 沪公网安备 31011502012228号